Safety and efficacy of high-dose G-CSF (24 mcg/kg) for PBSC mobilisation in children

被引：0
|
作者：
Alcorta, I
Estella, J
Toll, T
Rives, S
Mateo, M
机构：
来源：
BONE MARROW TRANSPLANTATION | 2001年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [31] Role of G-CSF after High-Dose Post-Transplantation Cyclophospamide
    Elayan, Mohammed M.
    Li, Belinda K.
    Battiwalla, Minoo
    Bachier, Carlos R.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S143 - S144
  • [32] Role of G-CSF after High-Dose Post-Transplantation Cyclophospamide
    Elayan, Mohammed M.
    Bachier, Carlos R.
    Battiwalla, Minoo
    Siler, Darby
    BLOOD, 2018, 132
  • [33] Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors
    C Martínez
    A Urbano-Ispizua
    P Marín
    A Merino
    M Rovira
    E Carreras
    E Montserrat
    Bone Marrow Transplantation, 1999, 24 : 1273 - 1278
  • [34] Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilization in healthy donors
    Martínez, C
    Urbano-Ispizua, A
    Marín, P
    Merino, A
    Rovira, M
    Carreras, E
    Montserrat, E
    BONE MARROW TRANSPLANTATION, 1999, 24 (12) : 1273 - 1278
  • [35] FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children
    McCarthy, AJ
    Pitcher, LA
    Hann, IM
    Oakhill, A
    MEDICAL AND PEDIATRIC ONCOLOGY, 1999, 32 (06): : 411 - 415
  • [36] FLAG (fludarabine, high-dose cytarabine and G-CSF) for refractory and high-risk relapsed acute leukemia in children
    Sarper, N
    Yalman, N
    MEDICAL AND PEDIATRIC ONCOLOGY, 2000, 34 (02): : 163 - 163
  • [37] Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies
    Awan, F.
    Kochuparambil, S. T.
    Falconer, D. E.
    Cumpston, A.
    Leadmon, S.
    Watkins, K.
    DeRemer, D.
    Jillella, A.
    Craig, M.
    Hamadani, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 (10) : 1279 - 1284
  • [38] Peripheral blood stem cell (PBSC) mobilization with high-dose vs. low-dose G-CSF: Analysis of a case control series.
    D'Cunha, N
    Stanford, BL
    Hardwicke, F
    Kolb, W
    Cobos, E
    BLOOD, 2003, 102 (11) : 953A - 953A
  • [39] Evaluation of the ESHAP regimen followed by G-CSF for PBSC mobilisation: A matched pairs analysis compared to low dose cyclophosphamide 1.5g/m(2) plus G-CSF.
    Watts, MJ
    Sullivan, AM
    Leverett, D
    MacMillan, AK
    Patterson, K
    Devereux, S
    Goldstone, AH
    Linch, DC
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 167 - 167
  • [40] A randomised study of 10 μg/kg/day (single dose) vs 2 x 5 μg/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients
    Carrión, R
    Serrano, D
    Gómez-Pineda, A
    Díez-Martín, JL
    BONE MARROW TRANSPLANTATION, 2003, 32 (06) : 563 - 567
12345